Join
Live feed
·
PRReleasevia Quantisnow
Kairos Pharma Ltd. logo

Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics

ByQuantisnow·Wall Street's wire, on your screen.
KAPA· Kairos Pharma Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KAPA (Kairos Pharma Ltd.) and more on Quantisnow.